The present invention provides oligopeptides, in particular, Ang-(1-7) derivatives, and methods for using and producing the same. In one particular embodiment, oligopeptides of the invention have higher blood-brain barrier penetration and/or in vivo half-life compared to the native Ang-(1-7), thereby allowing oligopeptides of the invention to be used in a wide variety of clinical applications including in treatment of cognitive dysfunction and/of impairment.

The present invention provides oligopeptides, in particular, Ang-(1-7) derivatives, and methods for using and producing the same. In one particular embodiment, oligopeptides of the invention have higher blood-brain barrier penetration and/or in vivo half-life compared to the native Ang-(1-7), thereby allowing oligopeptides of the invention to be used in a wide variety of clinical applications including in treatment of cognitive dysfunction and/of impairment.

This document provides methods and materials involved in assessing renal structural alterations (e.g., renal fibrosis, glomerular basement thickening, mesangial matrix expansion, swollen podocytes, and foot processes effacement) as well as methods and materials involved in assessing outcomes. For example, methods and materials for using the level of urinary CNP (e.g., a urinary to plasma CNP ratio) to determine whether or not a mammal is developing renal structural alterations (e.g., renal fibrosis, glomerular basement thickening, mesangial matrix expansion, swollen podocytes, and foot processes effacement) as well as methods and materials for using the level of urinary CNP levels to identify patients having an increased likelihood of experiencing a poor outcome are provided.

The present invention provides oligopeptides, in particular, Ang-(1-7) derivatives, and methods for using and producing the same. In one particular embodiment, oligopeptides of the invention have higher blood-brain barrier penetration and/or in vivo half-life compared to the native Ang-(1-7), thereby allowing oligopeptides of the invention to be used in a wide variety of clinical applications including in treatment of cognitive dysfunction and/of impairment.

The present invention provides oligopeptides, in particular, Ang-(1-7) derivatives, and methods for using and producing the same. In one particular embodiment, oligopeptides of the invention have higher blood-brain barrier penetration and/or in vivo half-life compared to the native Ang-(1-7), thereby allowing oligopeptides of the invention to be used in a wide variety of clinical applications including in treatment of cognitive dysfunction and/of impairment.

This application describes a family of compounds acting as -arrestin effectors. Such compounds may provide significant therapeutic benefit in the treatment of chronic and acute cardiovascular diseases.

This application describes a family of compounds acting as -arrestin effectors. Such compounds may provide significant therapeutic benefit in the treatment of chronic and acute cardiovascular diseases.

The present invention relates to a polyamide resin composition having substantially improved heat resistance and oxidation resistance. The polyamide resin composition comprises a polyamide copolymer having high heat resistance and high rigidity, glass fiber, citric acid and ethylenediaminetetraacetic acid (EDTA) which can rapidly cause surface oxidation with glass fiber, such that a highly dense oxide film can be formed on a polymer surface at high temperatures for a long time. Accordingly, the polyamide resin composition of the present invention can prevent oxidation and thermal decomposition by exterior oxygen and heat, and have substantially improved physical properties such as impact strength, tensile strength, flexural strength and elongation.

The present invention relates to a polyamide resin composition having substantially improved heat resistance and oxidation resistance. The polyamide resin composition comprises a polyamide copolymer having high heat resistance and high rigidity, glass fiber, citric acid and ethylenediaminetetraacetic acid (EDTA) which can rapidly cause surface oxidation with glass fiber, such that a highly dense oxide film can be formed on a polymer surface at high temperatures for a long time. Accordingly, the polyamide resin composition of the present invention can prevent oxidation and thermal decomposition by exterior oxygen and heat, and have substantially improved physical properties such as impact strength, tensile strength, flexural strength and elongation.

The present invention provides methods for limiting development of skin wounds, and also for treatment of one or more of erythemas, blisters, rashes, pruritis, contact dermatitis, psoriasis, eczema, acne, and athlete's foot.